Phenotype-Locked CAR-Tregs Show Promise

The interim LIBERATE data on QEL-001, an anti-HLA-A2 CAR-Treg therapy, involved nine liver transplant patients. The trial showed no serious adverse events or dose-limiting toxicities. All five patients in the expansion cohort who underwent immunosuppression weaning successfully ceased treatment with the calcineurin inhibitor tacrolimus without signs of organ rejection for at least six months. The core of Quell's approach is its proprietary Foxp3 Phenotype Lock™ module. This technology forces high expression of the transcription factor FOXP3, which is crucial for Treg stability and function. This addresses a key manufacturing challenge in Treg therapies: preventing the cells from converting into pro-inflammatory effector T cells, especially within an inflammatory environment. Data showed the phenotype-locked CAR-Tregs persisted for over a year in circulation, maintained key functional markers like Foxp3 and CTLA4, and showed a 10-20% enrichment in the transplanted liver tissue compared to less than 1% in the blood. This trafficking to the target organ is a critical factor for localized immunosuppression, a key advantage over systemic drugs that have broad side effects like increased risk of infection and cancer. Current immunosuppressants, like calcineurin inhibitors, while effective, are associated with significant side effects including metabolic syndrome, hypertension, and kidney toxicity. The goal of therapies like QEL-001 is to induce operational tolerance, allowing patients to reduce or eliminate the need for these lifelong, systemic drugs. While full withdrawal wasn't achieved in all patients without mild rejection, the ability to wean off tacrolimus is a significant step. The autologous nature of QEL-001 presents logistical and cost challenges common in cell therapy manufacturing, requiring complex processes for each patient. The variability of starting patient material is a major hurdle for process performance and scalability, necessitating robust data management and automation systems to ensure consistency and quality of the final cell product. Following these results, Quell, led by CEO Iain McGill, will seek a partner to advance the QEL-001 liver transplant program. The company is now prioritizing its capital on QEL-005, a CD19-targeting CAR-Treg for complex autoimmune diseases like rheumatoid arthritis, which represents a larger market and a faster path to further clinical data. This strategic shift reflects the broader biotech trend of leveraging platform validation in one indication to pivot to more commercially lucrative opportunities. Quell's work is part of a broader movement to engineer Tregs for therapeutic use in transplantation and autoimmune diseases. Key challenges for the field include optimizing CAR design, ensuring long-term in vivo persistence, and standardizing manufacturing protocols to ensure the purity and stability of the final cell product. Advances in gene editing, such as CRISPR, and process automation will be critical for overcoming these hurdles. The company's platform also includes a safety switch, a common feature in advanced cell therapies designed to mitigate potential risks. Quell is also collaborating with AstraZeneca on CAR-Treg programs for Type 1 Diabetes and Inflammatory Bowel Disease and is exploring induced pluripotent stem cells (iPSCs) to develop allogeneic, or "off-the-shelf," Treg therapies, which could significantly improve manufacturing scalability and accessibility.